Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere and Epitomics Form mAb Development Partnership

publication date: Mar 13, 2009

Simcere Pharma (先声药业) and San Francisco-based Epitomics, Inc. will collaborate to develop anti-cancer drugs using RabMAb®, Epitomics’ humanized rabbit monoclonal antibodies. Until now, Epitomics has concentrated its efforts on applying RabMAb® to develop diagnostic tools. The Simcere collaboration will be the first attempt to develop humanized antibody therapeutics from the rabbit antibodies. More details...

Stock Symbol: (NYSE: SCR)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital